4. Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)
Number of Hedge Fund Holders — 44
Number of Billionaire Holders — 19
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) stands out among these biotechnology stocks through a combination of growing product sales and positive quarterly earnings.
Second-quarter ZORYVE net product revenue reached $129.9 million, increasing 59% year over year and 23% sequentially. Management raised its full-year 2026 net product-sales outlook to $525 million–$540 million.
The business also generated $15 million in quarterly net income and $12.6 million in operating cash flow. Those results provide concrete evidence that revenue growth was translating into financial improvement.
“Our strong second quarter results reflect the continued strength of the ZORYVE franchise,” CEO Frank Watanabe said.
Further expansion could come from broader pediatric use. The FDA accepted a supplemental application for ZORYVE cream 0.05% in infants with mild-to-moderate atopic dermatitis, assigning a February 23, 2027 target action date.
An October 9 update highlighted presentations of infant-study data alongside research across psoriasis and seborrheic dermatitis. The company’s commercial strategy centers on once-daily, non-steroidal topical formulations across chronic inflammatory skin conditions.
Pediatric expansion requires particular care in evaluating formulation, age group, and approved indication. Positive trial findings in infants do not mean the treatment is already authorized for that population.
The company is also expanding access initiatives and its commercial reach. That creates an operating question for investors: whether additional prescriptions and broader patient eligibility can generate enough revenue to justify the supporting sales and development costs.
For investors seeking commercial-stage biotech stocks, established product demand and positive cash generation provide a different analytical starting point from early clinical programs.
Ranking rationale: Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) ranks fourth with 19 billionaire holders. Its ZORYVE sales growth, quarterly profitability, and potential pediatric expansion support the investment case, while maintaining commercial momentum remains essential.
